Savara reports first quarter 2025 financial results and provides a business update

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending march 31, 2025 and provided a business update. “at the end of 1q 2025, we announced the on-time submission of the molbreevi bla to the fda for the treatment of autoimmune pap and requested priority review,” said matt pauls, chair and chief executive officer, savara. “if priority review.
SVRA Ratings Summary
SVRA Quant Ranking